肿瘤标志物在左右半大肠腺癌中的研究价值及意义(4)
[14] Zhu ZM，Chen Z，Chen CL，et al. Opposite variation ten？鄄dencies of serum CA724 levels in patients with colon and rectal carcinoma [J]. Mol Clin Oncol，2014，2(1)：139-145.
[15] Torre LA，Bray F，Siegel RL，et al. Global cancer stati？鄄stics，2012. [J]. Ca A Cancer Journal for Clinicians，2015， 65(2)：87-108.
[16] 陈蕾，姜北海，邸佳柏.CA199在判断CEA正常的中晚期结直肠癌患者预后中的价值[J].临床研究与应用，2015， 42(15)：743-750.
[17] Wang J，Wang X，Yu F，Chen J，et al. Combined detec？鄄tion of preoperative serum CEA，CA19-9 and CA242 improve prognostic prediction of surgically treated color？鄄ectal cancer patients [J]. Int J Clin Exp Pathol，2015，8(11)：14 853-14 863.
[18] Verdaguer H，Saurí T，Macarulla T. Predictive and pro？鄄gnostic biomarkers in personalized gastrointestinal cancer treatment [J]. J Gastrointest Oncol，2017，8(3)：405-417.
[19] Grady WM，Pritchard CC. Molecular alterations and bio？鄄markers in colorectal cancer [J]. Toxicologic Pathology，2014， 42(1)：124.
[20] Gao XH，Yu GY，Gong HF，et al. Differences of protein expression profiles，KRAS and BRAF mutation，and prognosis in right-sided colon，left-sided colon and rectal cancer [J]. Sci Rep，2017，7(1)：7882.
[21] Kara O，Duman BB，Kara B，et al. Analysis of PTEN，VEGF，HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy [J]. Asian Pac J Cancer Prev，2012，13(12)：6397-6401.
(收稿日期：2017-07-27 本文編辑：任 念), http://www.100md.com(张文君 戈伟 伍龙)
[15] Torre LA，Bray F，Siegel RL，et al. Global cancer stati？鄄stics，2012. [J]. Ca A Cancer Journal for Clinicians，2015， 65(2)：87-108.
[16] 陈蕾，姜北海，邸佳柏.CA199在判断CEA正常的中晚期结直肠癌患者预后中的价值[J].临床研究与应用，2015， 42(15)：743-750.
[17] Wang J，Wang X，Yu F，Chen J，et al. Combined detec？鄄tion of preoperative serum CEA，CA19-9 and CA242 improve prognostic prediction of surgically treated color？鄄ectal cancer patients [J]. Int J Clin Exp Pathol，2015，8(11)：14 853-14 863.
[18] Verdaguer H，Saurí T，Macarulla T. Predictive and pro？鄄gnostic biomarkers in personalized gastrointestinal cancer treatment [J]. J Gastrointest Oncol，2017，8(3)：405-417.
[19] Grady WM，Pritchard CC. Molecular alterations and bio？鄄markers in colorectal cancer [J]. Toxicologic Pathology，2014， 42(1)：124.
[20] Gao XH，Yu GY，Gong HF，et al. Differences of protein expression profiles，KRAS and BRAF mutation，and prognosis in right-sided colon，left-sided colon and rectal cancer [J]. Sci Rep，2017，7(1)：7882.
[21] Kara O，Duman BB，Kara B，et al. Analysis of PTEN，VEGF，HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy [J]. Asian Pac J Cancer Prev，2012，13(12)：6397-6401.
(收稿日期：2017-07-27 本文編辑：任 念), http://www.100md.com(张文君 戈伟 伍龙)